Molecular interactions of new pregnenedione derivatives

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 10, 2003, Pages 1132-1136

  Bratoeff, Eugene ^a   Ramírez, Elena ^a   Flores, Eugenio ^a   Valencia, Norma ^a   Sánchez, Mauricio ^b   Heuze, Ivonne ^b   Cabeza, Marisa ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

5 reductase inhibition; Androgen receptor; Novel steroid; Pregnenedione derivative; Prostate

Indexed keywords

16BETA METHYL 17ALPHA TOLUOYLOXYPREGNA 1,4,6 TRIENE 3,20 DIONE; 17ALPHA (4 BROMOBENZOYLOXY) 6 METHYLENEPREGN 4 ENE 3,20 DIONE; 17ALPHA HYDROXY 16BETA METHYLPREGNA 1,4,6 TRIENE 3,20 DIONE; 17ALPHA HYDROXY 6 METHYLENEPREGN 4 ENE 3,20 DIONE; 6 METHYLENE 17ALPHA TOLUOYLOXYPREGN 4 ENE 3,20 DIONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE; RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROGESTERONE; STEROID 5ALPHA REDUCTASE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HAMSTER; IC 50; MALE; NONHUMAN; RECEPTOR AFFINITY; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; METABOLISM; PHYSIOLOGY; PROSTATE; SYNTHESIS; SYRIAN HAMSTER;

ANIMALS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; MESOCRICETUS; PROGESTERONE; PROSTATE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 2442507805     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.1132     Document Type: Article

References (18)

1. Li X., Chen C., Singh S. M., Labrie F., Steroids, 60, 430-441 (1995).
2. Imperato-McGinley J., Gautier L., Peterson R. E., Science, 186, 1213-1215 (1974).
3. Walsh P. C., Madden J. D., Harrod M. J., Goldtein J. L., McDonald P. C., Wilson J. D., New Engl. J. Med., 291, 944-949 (1974).
4. Imperato-McGinley J., Peterson R. E., Gautier T., Sturla E., J. Steroid Biochem., 11, 637-645 (1979).
5. Geller J., Albert J., Lopez D., Geller S., Niwayama G., J. Clin. Endocrinol. Metab., 43, 486-488 (1976).
6. Sitteri P. K., Wilson J. D., Mayfield J. A., J. Clin. Invest., 49, 1737-1745 (1970).
7. Anderson S., Berman D. M., Jenkins E. P., Russell D. W., Nature (London), 354, 159-161 (1991).
8. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., leblanc G., Durocher F., Paquet N., Endocrinology, 131, 1571-1573 (1992).
9. McConnel J., Wilson J. D., George F. G., Geller J., Pappas F., Stoner E., J. Clin. Endocrin. Meta., 74, 505-509 (1992).
10. Guess H. A., Heyese J. F., Gormely G. J., Prostate, 22, 31-37 (1993).
11. Ramirez E., Cabeza M., Heuze I., Gutierrez E., Bratoeff E., Membrillo M., Lira A., Chem. Pharm. Bull., 50, 15-20 (2002).
12. Cabeza M., Bratoeff E., Flores E., Ramirez E., Calleros J., Montes D., Quiroz A., Heuze I., Chem. Pharm. Bull., 50, 1447-1452 (2002).
13. Cabeza M., Heuze I., Bratoeff E., Murillo E., Ramirez E., Lira A., Chem. Pharm. Bull., 49, 1081-1084 (2001).
14. Liang T., Cascieri M. A., Cheung A. H., Reynolds G. F., Rasmusson G. H., Endocrinology, 117, 571-579 (1985).
15. Bradford M. M., Anal. Biochem., 72, 248-254 (1986).
16. Hirosumi J., Nakayama O., Fagan T., Sawada K., Chida N., Inami M., Takahashi S., Kojo H., Notsu Y., Okuhara M., J. Steroid Biochem Molec. Biol., 52, 357-363 (1995).
17. Bratoeff E., Ramirez E., Murillo E., Flores G., Cabeza M., Curr. Med. Chem., 6, 1107-1123 (1999).
18. Cheng Y. C., Prusoff W. H., Biochem. Pharmacol., 22, 3099-3108 (1973).